IHL’s psilocybin treatment takes 2 steps forward, with a boost from the FDA and ethics approval to commence trials at Monash University

Across its extensive product suite, clinical stage pharmaceutical development company Incannex Healthcare is developing a unique psilocybin therapy for the treatment of generalised anxiety disorder (GAD).